Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin

被引:28
|
作者
Gibson, JL
Ekevall, K
Walker, I
Greer, IA
机构
[1] Univ Glasgow, Glasgow Royal Infirm, Dept Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland
[2] Glasgow Royal Matern Hosp, Glasgow, Lanark, Scotland
来源
关键词
D O I
10.1111/j.1471-0528.1998.tb10212.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Low molecular weight heparins are used extensively for thromboprophylaxis. The aim of this study was to compare the activity of the low molecular weight heparin, enoxaparin, 20 mg and 40 mg, given once per day with unfractionated heparin, 7500iu given twice per day, in terms of their anti-Xa activity in puerperal women following caesarean section and with an additional risk factor for venous thromboembolism. Seventeen women were randomised to receive one of the three treatments. The anti-Xa activity associated with each treatment was measured prior to treatment and at 2, 4, 6, 12 and 24 hours. The mean anti-Xa values of the groups receiving enoxaparin, 20 mg and 40 mg, were significantly higher than those of the group receiving unfractionated heparin. There was no difference between the two enoxaparin groups in terms of the anti-Xa activity profiles. This study suggests that the use of enoxaparin is superior to unfractionated heparin in terms of anti-Xa activity.
引用
收藏
页码:795 / 797
页数:3
相关论文
共 50 条
  • [41] Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes
    Toulon, Pierre
    Appert-Flory, Anny
    Fischer, Florence
    Buvat, Sylvain
    Jambou, Didier
    Mahagne, Marie-Helene
    THROMBOSIS RESEARCH, 2020, 186 : 7 - 12
  • [42] Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin, Hyoshim
    Koh, Eun-Ha
    Lee, Gyeong-Won
    Song, Haa-Na
    Kim, Hyun-Young
    Park, Sungwoo
    JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2020, 8 (05) : 741 - 747
  • [43] Discordant aPTT and Anti-Xa Values and Outcomes in Hospitalized Patients Treated with Intravenous Unfractionated Heparin
    Price, Elizabeth A.
    Jin, Jing
    Nguyen, Huong
    Krishnan, Gomathi
    Bowen, Raffick
    Zehnder, James L.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (02) : 151 - 158
  • [44] Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
    Amin, Alpesh
    Kartashov, Alex
    Ngai, Wilson
    Steele, Kevin
    Rosenthal, Ning
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [45] Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves
    Izaguirre, R
    De la Pña, A
    Ramírez, A
    Cortina, E
    Huerta, M
    Salazar, E
    PROCEEDINGS OF THE FORTY-FIFTH ANNUAL MEETING OF THE WESTERN PHARMACOLOGY SOCIETY, 2002, 45 : 127 - 128
  • [46] Anti-Xa activity relates to outcome in acute coronary syndromes treated with Enoxaparin
    Montalescot, G
    Collet, JP
    Payot, L
    Choussat, R
    Beygui, F
    Gallois, V
    Metzger, JP
    Thomas, D
    CIRCULATION, 2003, 108 (17) : 501 - 501
  • [47] Comparison Between Activated Partial Thromboplastin Time and Anti-Xa Heparin Assays on Patients on Unfractionated Heparin Therapy: Does the Prothrombin Time Matter?
    Pearlman, Eugene
    Singh, Harman
    Willard, Jennifer
    Moore, Darlene
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 : A128 - A128
  • [48] CHARACTERIZATION OF PERSISTENT ANTI-XA ACTIVITY FOLLOWING ADMINISTRATION OF THE LOW-MOLECULAR-WEIGHT HEPARIN ENOXAPARIN SODIUM (CLEXANE)
    BRIEGER, D
    DAWES, J
    THROMBOSIS AND HAEMOSTASIS, 1994, 72 (02) : 275 - 280
  • [49] SUBTHERAPEUTIC ANTI-XA ACTIVITY OF STANDARD ENOXAPARIN DOSING IN THROMBOPHYLAXIS IN NEPHROTIC SYNDROME
    Matyjek, Anna
    Literacki, Slawomir
    Rymarz, Aleksandra
    Rozmyslowicz, Tomasz
    Niemczyk, Stanislaw
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [50] Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
    McGarry L.J.
    Stokes M.E.
    Thompson D.
    Thrombosis Journal, 4 (1)